May 1, 2023Open Access

Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study

Structured PICO

Is P2Y12 inhibitor monotherapy directly following PCI feasible and safe in patients with NSTE-ACS?

Population

Patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) undergoing percutaneous coronary intervention (PCI)

Intervention

P2Y12 inhibitor monotherapy directly following PCI

Outcome

Feasibility and safetysafety

First-in-human evidence demonstrates the feasibility and safety of direct P2Y12 inhibitor monotherapy after PCI in NSTE-ACS patients, highlighting the need for future randomized controlled trials.

Abstract

This study provides first-in-human evidence that P2Y12 inhibitor monotherapy directly following PCI for NSTE-ACS is feasible, without any overt safety concerns, and highlights the need for randomised controlled trials comparing direct P2Y12 inhibitor monotherapy with the current standard of care.

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Sangen et al. (Mon,) studied this question.

synapsesocial.com/papers/69d572e975589c71d767e901 https://doi.org/https://doi.org/10.4244/eij-d-22-00886

AI에게 질문

Bookmark

View Full Paper